National Working Group Meeting on ALK Diagnostics in Lung Cancer

Wendy Cooper; Stephen Fox; Sandra O'Toole; Adrienne Morey; Glenn Frances; Nick Pavlakis; Kenneth O'Byrne; Andrew Dettrick; Trishe Leong; Vivek Rathi; Dominic Spagnolo; Chris Hemmings; Mahendra Singh; David Moffat; Ming-Sound Tsao; Keith Wilner; Richard Buller; Susan Pitman Lowenthal; Shams Arifeen; Justin Binko; Mahmood Alam

doi:10.1111/ajco.12190

National Working Group Meeting on ALK Diagnostics in Lung Cancer

Wendy Cooper
, Stephen Fox
, Sandra O'Toole
, Adrienne Morey
, Glenn Frances
, Nick Pavlakis
, Kenneth O'Byrne
, Andrew Dettrick
, Trishe Leong
, Vivek Rathi
, Dominic Spagnolo
, Chris Hemmings
, Mahendra Singh
, David Moffat
, Ming-Sound Tsao
, Keith Wilner
, Richard Buller
, Susan Pitman Lowenthal
, Shams Arifeen
, Justin Binko

Mahmood Alam

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors.

Original language	English
Pages (from-to)	11-17
Number of pages	7
Journal	Asia-Pacific Journal of Clinical Oncology
Volume	10
Issue number	Suppl. 2
DOIs	https://doi.org/10.1111/ajco.12190
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/ajco.12190

Cite this

Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakis, N., O'Byrne, K., Dettrick, A., Leong, T., Rathi, V., Spagnolo, D., Hemmings, C., Singh, M., Moffat, D., Tsao, M.-S., Wilner, K., Buller, R., Pitman Lowenthal, S., Arifeen, S., ... Alam, M. (2014). National Working Group Meeting on ALK Diagnostics in Lung Cancer. Asia-Pacific Journal of Clinical Oncology, 10(Suppl. 2), 11-17. https://doi.org/10.1111/ajco.12190

@article{ae187850f5564887a079c2608606e60b,

title = "National Working Group Meeting on ALK Diagnostics in Lung Cancer",

abstract = "The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors.",

author = "Wendy Cooper and Stephen Fox and Sandra O'Toole and Adrienne Morey and Glenn Frances and Nick Pavlakis and Kenneth O'Byrne and Andrew Dettrick and Trishe Leong and Vivek Rathi and Dominic Spagnolo and Chris Hemmings and Mahendra Singh and David Moffat and Ming-Sound Tsao and Keith Wilner and Richard Buller and \{Pitman Lowenthal\}, Susan and Shams Arifeen and Justin Binko and Mahmood Alam",

year = "2014",

doi = "10.1111/ajco.12190",

language = "English",

volume = "10",

pages = "11--17",

journal = "Asia-Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "Suppl. 2",

}

Cooper, W, Fox, S, O'Toole, S, Morey, A, Frances, G, Pavlakis, N, O'Byrne, K, Dettrick, A, Leong, T, Rathi, V, Spagnolo, D, Hemmings, C, Singh, M, Moffat, D, Tsao, M-S, Wilner, K, Buller, R, Pitman Lowenthal, S, Arifeen, S, Binko, J & Alam, M 2014, 'National Working Group Meeting on ALK Diagnostics in Lung Cancer', Asia-Pacific Journal of Clinical Oncology, vol. 10, no. Suppl. 2, pp. 11-17. https://doi.org/10.1111/ajco.12190

TY - JOUR

T1 - National Working Group Meeting on ALK Diagnostics in Lung Cancer

AU - Cooper, Wendy

AU - Fox, Stephen

AU - O'Toole, Sandra

AU - Morey, Adrienne

AU - Frances, Glenn

AU - Pavlakis, Nick

AU - O'Byrne, Kenneth

AU - Dettrick, Andrew

AU - Leong, Trishe

AU - Rathi, Vivek

AU - Spagnolo, Dominic

AU - Hemmings, Chris

AU - Singh, Mahendra

AU - Moffat, David

AU - Tsao, Ming-Sound

AU - Wilner, Keith

AU - Buller, Richard

AU - Pitman Lowenthal, Susan

AU - Arifeen, Shams

AU - Binko, Justin

AU - Alam, Mahmood

PY - 2014

Y1 - 2014

N2 - The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors.

AB - The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors.

UR - http://handle.uws.edu.au:8081/1959.7/546057

U2 - 10.1111/ajco.12190

DO - 10.1111/ajco.12190

M3 - Article

SN - 1743-7555

VL - 10

SP - 11

EP - 17

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

IS - Suppl. 2

ER -

National Working Group Meeting on ALK Diagnostics in Lung Cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this